ClinicalTrials.gg
RecruitingNCT07458516IMPORTANTUpdated Oct 23, 2026

Longitudinal Observational Study of Diabetic Retinopathy Progression in Type 2 Diabetes Patients

An observational study in Diabetic Retinopathy, Diabetes Mellitus, Type 2 and Diabetic Complication, sponsored by Association for Innovation and Biomedical Research on Light and Image. Recruiting at 1 site in Portugal. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Association for Innovation and Biomedical Research on Light and Image · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.
Updated Oct 23, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
35 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image — 2 open to participants now, 3 under way, none of them phase 3. Diabetic Retinopathy · Association for Innovation and Biomedical Research on Light and Image.

Planned enrollment
7th of 16
100 · median 81
Started
2025
with 1 other
Observational
16 of 18
2 open now
Registered
18th of 18
by date

Among the 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image, this one is the 7th largest by planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2025, is one of 16 observational ones, and was the 18th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

2 of the 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 35 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image, or all of them as a file.
02

Study summary

The purpose of this clinical study is to explore structural and functional imaging and systemic biomarkers of diabetic retinopathy (DR) progression, in eyes from Type 2 Diabetes (T2D) patients with moderate to severe non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (PDR) using state of the art methodologies, commonly applied in clinical practice, over a period of two years. This study will provide longitudinal data to better understand retinal changes in moderate to severe diabetic retinopathy and early proliferative diabetic retinopathy and help guide timely interventions to prevent vision loss. One or two eligible eyes per participant may be included in the study. The study will evaluate retinal vascular closure, ischemia, leakage, neurodegeneration, macular edema and microaneurysm dynamics and their association with disease progression.

Read the detailed description

Diabetes Mellitus (DM) is an important public health problem, affecting about 589 million people in the world, and expected to reach 853 million by 2050. Active screening for DR is important because most patients may be asymptomatic until the very late stages. Nonproliferative diabetic retinopathy (NPDR) itself may be associated with reduced visual function and quality of life measures (Willis et al., 2017).

The molecular pathophysiology of DR is complex, and a complete model of the disease is still being elucidated. The oxidative stress in diabetes upregulates multiple cytokines and chemokines, such as vascular endothelial growth factor (VEGF), angiopoietins, tumour necrosis factor (TNF), interleukins (ILs) and matrix metalloproteinases (MMPs) that leads to breakdown of the blood-retinal-barrier (BRB). Also, retinal capillary obstruction (leukostasis) or dropout (apoptosis of vascular cells) in diabetes leads to tissue ischemia and hypoxia causing increased retinal VEGF expression through transcriptional regulation by hypoxia-inducible factor 1 alpha (HIF-1α) (Arjamaa \& Nikinmaa, 2006; Whitehead et al., 2019).

The risk of developing DR complications increases over time, with increasing areas of capillary nonperfusion underpinning progression to more severe forms and development of complications as PDR or diabetic macular edema (DME), driven by hypoxia and hyperexpression of proangiogenic growth factors. However, this risk varies widely, independently of metabolic control. Differentiating patients with higher risk of progression and development of vision-threatening complications (VTC; DME and PDR) is of paramount importance for efficient treatment of the disease in order to prevent vision disability and achieve better visual outcomes. Recent developments in terms of retina imageology, namely Optical Coherence Tomography (OCT) and OCT Angiography (OCTA), have improved the understanding of DR pathophysiology and evolution, with a better characterization of venous abnormalities including occlusion, tortuosity, dilatation, looping or beading. OCTA examination is faster and safer compared to examination with fluorescein angiography (FA), and it can visualise the retinal vasculature in any layer of the retina. OCTA has the potential to become the examination of choice to identify eyes at risk of progression and development of VTC. Ultra-widefield fluorescein angiography (UWF-FFA) further enables the assessment of retinal ischemia and retinal leakage over a wider retinal area, providing additional biomarkers of disease severity and progression.

The purpose of this observational, non-interventional, prospective, and longitudinal clinical study is to explore explore structural and functional imaging and systemic biomarkers of diabetic retinopathy (DR) progression, in eyes from Type 2 Diabetes (T2D) patients with moderate to severe NPDR and mild PDR - Diabetic Retinopathy Severity Scale (DRSS) levels 43, 47, 53, and 61 - using state of the art methodologies, commonly applied in clinical practice. One or two eligible eyes from the same participant may be included in the study if all eligibility criteria are met.

Follow-up visits will be performed every 6 months for 2 years with a total of 5 visits. Participants will undergo the following assessments: multimodal retinal imaging, including OCT, OCTA, ultra-widefield (UWF) fundus fluorescein angiography (FFA) and fundus photography (FP), and color fundus photography (CFP); functional testing: best corrected visual acuity (BCVA) and microperimetry (Macular Integrity Assessment, MAIA); collection of systemic health variables, including glycated hemoglobin (HbA1c), blood pressure, diabetes duration, and relevant comorbidities. UWF-FFA assessments will be used to quantify both ischemic and leakage areas and to evaluate their longitudinal changes over time. Statistical analyses will account for repeated measurements and potential inter-eye correlation when both eyes from the same participant are included.

03

Conditions studied

  • Diabetic Retinopathy
  • Diabetes Mellitus, Type 2
  • Diabetic Complication
  • Retinal Disease

Keywords

  • Disease biomarkers
04

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study Population: Eyes with moderate to severe NPDR and mild PDR. Ideally, the distribution of eyes will be as follows: 40 for Diabetic Retinopathy Severity Scale (DRSS) level 43, 40 for DRSS level 47, and 20 for DRSS levels 53-61

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus (T2D) according to 1985 World Health Organization (WHO) criteria.
  • Age between 35 and 80 years.
  • Best-corrected visual acuity (BCVA) ≥ 69 letters (20/40).
  • Refraction with a spherical equivalent less than 5 diopters.
  • Non-proliferative diabetic retinopathy (NPDR; DRSS levels 43, 47, 53) or mild proliferative diabetic retinopathy (PDR; DRSS level 61: Neovascularization Elsewhere (NVE) \< ½ disc area in ≥ 1 quadrant, no Neovascularization of the Disc (NVD), no vitreous or sub-hyaloid hemorrhage), in which panretinal photocoagulation (PRP) and/or intravitreal anti-VEGF treatment can safely be deferred for at least 6 months, based on consensus between patient and investigator - using ETDRS criteria, 7-field equivalent area on ultra-widefield fundus imaging.
  • Ability to understand and sign the written Form (ICF).

Exclusion criteria

Exclusion Criteria:

  • Central subfield thickness (CST) > 400 μm (fluid allowed if CST ≤ 400 μm and foveal contour is normal, as determined by the Central Reading Centre, and treatment is not immediately required).
  • Any sign of retinal fibrovascular proliferation.
  • Uncontrolled glaucoma (intraocular pressure > 25 mmHg regardless of concomitant IOP-lowering medications) or neovascular glaucoma.
  • Any sign of iris neovascularization, vitreous, or pre-retinal hemorrhage.
  • Other retinal vascular diseases (ocular ischemic syndrome, retinal arterial or venous occlusion, exudative age-related macular degeneration, etc.).
  • Previous panretinal photocoagulation (PRP) or intravitreal injection treatment.
  • Any eye surgery within 6 months prior to the inclusion visit.
  • Significant media opacities including severe cataract, corneal scarring or edema, or vitreous hemorrhage that precludes fundus evaluation.
  • Pupil dilation \< 5 mm.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Changes in capillary perfusion density (PD) using OCTA

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in capillary non-perfusion using binarized vessel density (VD) as perfusion density (PD) in the superficial and deep retinal vascular layers assessed with Optical Coherence Tomography Angiography.

    Time frame: Baseline to 24 months

  2. Foveal Avascular Zone (FAZ) area

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in the area of the foveal avascular zone measured in square millimeters (mm²) using Optical Coherence Tomography Angiography automated segmentation tools across DRSS levels.

    Time frame: Baseline to 24 months

  3. Foveal Avascular Zone (FAZ) perimeter

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in the perimeter of the foveal avascular zone measured in millimeters (mm) using Optical Coherence Tomography Angiography automated segmentation tools across DRSS levels.

    Time frame: Baseline to 24 months

  4. Foveal Avascular Zone (FAZ) circularity

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in the circularity of the foveal avascular zone using Optical Coherence Tomography Angiography automated segmentation tools across DRSS levels.

    Time frame: Baseline to 24 months

  5. Changes in retinal ischemic area using UWF FFA

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in retinal ischemic area (mm2) across DRSS levels.

    Time frame: Baseline to 24 months

  6. Changes in central retinal thickness (CRT)

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in Central Retinal Thickness (CRT) assessed using Optical Coherence Tomography (OCT) across DRSS levels.

    Time frame: Baseline to 24 months

  7. Changes in central intraretinal fluid

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in intraretinal fluid (layer-specific) assessed using Optical Coherence Tomography (OCT) across DRSS levels.

    Time frame: Baseline to 24 months

  8. Changes in Disorganisation of Retinal Inner Layers (DRIL)

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in Disorganisation of Retinal Inner Layers (DRIL) assessed using Optical Coherence Tomography (OCT) across DRSS levels.

    Time frame: Baseline to 24 months

  9. Changes in Disorganisation of Retinal Outer Layers (DROL)

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in Disorganisation of Retinal Outer Layers (DROL) assessed using Optical Coherence Tomography (OCT) across DRSS levels.

    Time frame: Baseline to 24 months

  10. Changes in Ganglion Cell Layer (GCL) + Inner Plexiform Layer (IPL) thickness

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in Ganglion Cell Layer (GCL) + Inner Plexiform Layer (IPL) thickness assessed using Optical Coherence Tomography (OCT) across DRSS levels.

    Time frame: Baseline to 24 months

  11. DRSS severity level

    Evaluate the DRSS score (range 10-85; higher scores indicate worse severity) in Ultra-widefield fundus photography (UWF-FP).

    Time frame: Baseline to 24 months

  12. Changes in microaneurysm (MA) count

    Evaluate baseline differences and longitudinal changes (from baseline to months 6, 12, and 24) in MA number in colour fundus photography (CFP field 2) across DRSS levels.

    Time frame: Baseline to 24 months

  13. Changes in microaneurysm (MA) turnover

    Evaluate baseline differences and longitudinal changes (from baseline to months 6, 12, and 24) in MA turnover in colour fundus photography (CFP field 2) across DRSS levels.

    Time frame: Baseline to 24 months

  14. Changes in retinal leakage area using UWF-FFA

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in retinal leakage area measured using ultra-widefield fluorescein angiography (UWF-FFA).

    Time frame: Baseline to Month 24

Secondary outcomes

  1. Changes in DRSS levels

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in DRSS classification, including one-step and two-step changes across DRSS levels using ultra-widefield fluorescein angiography (UWF-FFA).

    Time frame: Baseline to 24 months

  2. Changes in Best Corrected Visual Acuity (BCVA)

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in BCVA, measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters.The BCVA letter score ranges from 0 to 100 (best score), and a gain in BCVA from baseline indicates an improvement in visual acuity.

    Time frame: Baseline to 24 months

  3. Macular sensitivity using Microperimetry

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in average macular sensitivity (dB), fixation indices P1 and P2 (%), and Bivariate Contour Ellipse Area (BCEA; 63% and 95%) across DRSS levels.

    Time frame: Baseline to 24 months

  4. Changes in Intraretinal Microvascular Abnormalities (IRMAs)

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in the presence and area of IRMAs using Swept-Source OCTA, UWF-FP and UWF-FFA.

    Time frame: Baseline to 24 months

  5. Changes in neovascularization (NV)

    Evaluate baseline differences and longitudinal changes (from baseline to month 24) in the presence and area of NV using Swept-Source OCTA, UWF-FP and UWF-FFA.

    Time frame: Baseline to 24 months

07

Study locations

1 of 1 sites recruiting
  • AIBILI-CEC (AIBILI-Clinical Trial Centre)
    Coimbra, 3000-548, Portugal
    Recruiting
08

References and documents

Publications

  • Arjamaa O, Nikinmaa M. Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp Eye Res. 2006 Sep;83(3):473-83. doi: 10.1016/j.exer.2006.01.016. Epub 2006 Jun 5. PubMed 16750526 ↗
  • Willis JR, Doan QV, Gleeson M, Haskova Z, Ramulu P, Morse L, Cantrell RA. Vision-Related Functional Burden of Diabetic Retinopathy Across Severity Levels in the United States. JAMA Ophthalmol. 2017 Sep 1;135(9):926-932. doi: 10.1001/jamaophthalmol.2017.2553. PubMed 28750122 ↗
  • Whitehead M, Osborne A, Widdowson PS, Yu-Wai-Man P, Martin KR. Angiopoietins in Diabetic Retinopathy: Current Understanding and Therapeutic Potential. J Diabetes Res. 2019 Aug 14;2019:5140521. doi: 10.1155/2019/5140521. eCollection 2019. PubMed 31485452 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

Of 75 non-industry observational studies under Diabetic Retinopathy, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13. This study's planned 24 months is below that.

Counting every sponsor, half of 92 studies reached it within 28 months; a quarter within 12 and three quarters within 61.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Dec 2027 → Nov 2027 and completion Jun 2028 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 9, 2026
StartActual
Nov 24, 2025
Primary completionEst.
Nov 2027was Dec 2027
CompletionEst.
Nov 2028was Jun 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2027→Nov 2027
Oct 23, 2026
Study completion
Jun 2028→Nov 2028
Oct 23, 2026
Eligibility
Revised
Oct 23, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Changes in capillary skeletonized vessel density (SVD)Now Changes in retinal leakage area using UWF-FFATime frame: Baseline to 24 months → Baseline to Month 24
Oct 23, 2026
Secondary outcomes
1 edited, 3 description edited
What changed in the outcomes
  • EditedRetinalMacular sensitivity using MAIA MicroperimetryTime frame: Baseline to 24 months
  • DescriptionChanges in DRSS levels: how it is measured was reworded
  • DescriptionChanges in Intraretinal Microvascular Abnormalities (IRMAs): how it is measured was reworded
  • DescriptionChanges in neovascularization (NV): how it is measured was reworded
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Primary completion Dec 2027→Nov 2027
    Study completion Jun 2028→Nov 2028
    Eligibility Revised
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Changes in capillary skeletonized vessel density (SVD)Now Changes in retinal leakage area using UWF-FFATime frame: Baseline to 24 months → Baseline to Month 24
    Secondary outcomes 1 edited, 3 description edited
    What changed in the outcomes
    • EditedRetinalMacular sensitivity using MAIA MicroperimetryTime frame: Baseline to 24 months
    • DescriptionChanges in DRSS levels: how it is measured was reworded
    • DescriptionChanges in Intraretinal Microvascular Abnormalities (IRMAs): how it is measured was reworded
    • DescriptionChanges in neovascularization (NV): how it is measured was reworded
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07458516
Lead sponsor
Association for Innovation and Biomedical Research on Light and Image
Collaborators
Fundação para a Ciência e a Tecnologia
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Nov 24, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Joana Tavares, PhD
Contact
jftavares@aibli.pt
+351239480137
Liliana C Soares, MsC
Contact
important_4c@aibili.pt
+351239480105/131
Inês P Marques, MD PhD
principal investigator · AIBILI - Associação para a Investigação Biomédica e Inovação em Luz e Imagem

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion